[Clinical application of vitamin K for hepatocellular carcinoma]

Clin Calcium. 2007 Nov;17(11):1693-9.
[Article in Japanese]


Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / prevention & control
  • Cell Division / drug effects
  • Drug Design
  • Drug Synergism
  • Drug Therapy, Combination
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / prevention & control
  • Neoplasm Recurrence, Local / prevention & control
  • Randomized Controlled Trials as Topic
  • Vitamin K 2 / pharmacology
  • Vitamin K 2 / therapeutic use*


  • Antineoplastic Agents
  • Vitamin K 2